Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor XI deficiency.

Niamh M O'connell1

  • 1The Katharine Dormandy Haemophilia Centre and Haemostasis Unit, The Royal Free and University College Medical School, London, UK.

Seminars in Hematology
|February 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of age on ISTH-BAT scores and low VWF diagnosis in the Zimmerman Program.

Blood advances·2025
Same author

Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF.

Blood·2025
Same author

Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies.

Blood·2023
Same author

A cross-sectional follow-up study of physical activity in adults with moderate and severe haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2023
Same author

Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.

Journal of thrombosis and haemostasis : JTH·2023
Same author

Physical activity, physical fitness and cardiometabolic risk amongst adults with moderate and severe haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2022
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Factor XI deficiency causes variable bleeding, particularly in areas of high fibrinolysis. Treatment strategies involve recombinant activated factor VII and tranexamic acid for surgical bleeding.

Area of Science:

  • Hematology
  • Coagulation Disorders
  • Genetics

Background:

  • Factor XI (FXI) deficiency presents with unpredictable bleeding tendencies, not always correlating with FXI coagulant activity.
  • Bleeding manifestations are often exacerbated in regions with high fibrinolytic activity.
  • FXI deficiency is rare overall but prevalent in specific populations, such as Ashkenazi Jews and Basques, with identified gene mutations and founder effects.

Purpose of the Study:

  • To review the role of Factor XI in the coagulation cascade.
  • To document factors influencing the bleeding tendency in FXI deficiency.
  • To discuss current treatment approaches for surgical bleeding in FXI-deficient patients.

Main Methods:

  • Literature review on Factor XI's role in hemostasis.

Related Experiment Videos

  • Analysis of factors modifying bleeding risk in FXI deficiency.
  • Review of therapeutic strategies for managing surgical bleeding.

    • Main Results:

    • Factor XI plays a role in coagulation, but its precise contribution to bleeding diathesis is complex.
    • High fibrinolytic activity significantly impacts bleeding severity in FXI deficiency.
    • Specific populations exhibit higher frequencies of FXI deficiency due to distinct genetic mutations.

    Conclusions:

    • Understanding FXI's role and modifying factors is crucial for managing bleeding disorders.
    • Combined therapy with recombinant activated factor VII and tranexamic acid shows promise for surgical bleeding in FXI deficiency.